Nchi: Nyuzilandi
Lugha: Kiingereza
Chanzo: Medsafe (Medicines Safety Authority)
Dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg
Pharmaco (NZ) Ltd
Dihydrocodeine hydrogen tartrate 60 mg (Equiv to dihydrocodeine 40 mg)
60 mg
Modified release tablet
Active: Dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg Excipient: Cetostearyl alcohol Hyetellose Lactose monohydrate Magnesium stearate Purified talc
Bottle, plastic, HDPE with PP child resistant closure, 60 tablets
Class C2 Controlled Drug
Class C2 Controlled Drug
Macfarlan Smith Ltd
DHC CONTINUS is indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and -the pain is opioid-responsive, and -requires daily, continuous, long term treatment. DHC CONTINUS is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. DHC CONTINUS is not indicated as an as-needed (PRN) analgesia.
Package - Contents - Shelf Life: Bottle, plastic, HDPE with PP child resistant closure - 60 tablets - 36 months from date of manufacture stored at or below 30°C - Bottle, plastic, Polypropylene - 60 tablets - 36 months from date of manufacture stored at or below 30°C
1989-10-17
DHC CONTINUS ® TABLETS _Dihydrocodeine hydrogen tartrate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you start using DHC CONTINUS ® . This leaflet answers some common questions about DHC CONTINUS ® . It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using DHC CONTINUS ® against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT USING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. Keep this leaflet with the medicine. You may need to read it again. WHAT DHC CONTINUS ® TABLETS ARE TAKEN FOR DHC CONTINUS ® tablets contain Dihydrocodeine hydrogen tartrate. Dihydrocodeine, belongs to a class of medicines called opioids, which are ‘pain relievers’. DHC CONTINUS® is used for the management of severe pain where other forms of treatment have failed, or should not be used or are not tolerated or are otherwise inappropriate to provide adequate management of pain. DHC CONTINUS® is used where the pain is responsive to opioids, and where the pain requires daily, continuous, long term treatment. Your doctor may have prescribed DHC CONTINUS ® for another reason. Ask your doctor if you have any questions about why DHC CONTINUS ® has been prescribed for you. As with all strong painkillers, your body may become used to you taking DHC CONTINUS ® tablets. Taking it may result in physical dependence. Physical dependence means that you may experience withdrawal symptoms if you stop taking DHC CONTINUS ® tablets suddenly, so it is important to take it exactly as directed by your doctor. This medicine is available only with a doctor's prescription. BEFORE YOU TAKE DHC CONTINUS ® _ _ _WHEN YOU MUST NOT USE IT _ DO NOT USE DHC CONTINUS ® IF YOU: are allergic (hypersensitive) to dihydrocodeine or any of the ingredients listed at the end of this leaflet; have severe breathing problems such as Soma hati kamili
NEW ZEALAND DATA SHEET DHC Continus tabs Jan 2024 Page 1 of 11 DHC CONTINUS® 60MG TABLETS Dihydrocodeine hydrogen tartrate 1 PRODUCT NAME DHC CONTINUS® 60mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dihydrocodeine hydrogen tartrate 60mg equivalent to 40mg dihydrocodeine Excipient(s) with known effect: Lactose anhydrous For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets: White, biconvex, capsule-shaped 12mm in length and 5mm wide, plain on one side and embossed DHC 60 on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DHC CONTINUS® is indicated for the management of severe pain where: • other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and • the pain is opioid-responsive, and • requires daily, continuous, long term treatment. DHC CONTINUS® is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. DHC CONTINUS® is not indicated as an as-needed (PRN) analgesia. 4.2 DOSE AND METHOD OF ADMINISTRATION _ADULTS AND CHILDREN OVER 12 YEARS OF AGE: _ The tablets should be taken at twelve-hourly intervals at a dose of 60-120mg twice daily depending on the severity of the patient’s pain. The maximum recommended dose is 240mg daily since higher doses do not provide any further analgesic effect. _CHILDREN 12 YEARS OR UNDER: _ Not recommended. _ELDERLY AND SPECIAL RISK GROUPS: _ NEW ZEALAND DATA SHEET DHC Continus tabs Jan 2024 Page 2 of 11 DHC CONTINUS® tablets should be administered initially at the lowest dose possible in elderly or debilitated patients, patients with impaired renal function, impaired hepatic function, or hypothyroidism. _METHOD OF ADMINISTRATION: _ DHC CONTINUS® tablets must be swallowed whole and not broken, chewed or crushed. 4.3 CONTRAINDICATIONS • Known hypersensitivity to dihydrocodeine hydrogen tartate or to any of the excipients (see section 6.1) • Severe chronic obstructive lung disease • Severe _cor pulmo Soma hati kamili